![](https://www.pdfsearch.io/img/4be206d87f7a805c2bf9dd7711f3f21e.jpg) Date: 2018-04-10 18:00:06
| | Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with SVPRapamycin Enables Sustained Reduction of Serum Uric Acid Levels by Mitigating Formation of Anti-DAdd to Reading ListSource URL: selectabio.comDownload Document from Source Website File Size: 1,35 MBShare Document on Facebook
|